Salesforce Climbs On Q1 Earnings, Revenue Beat. Full-Year Guidance Raised.

Salesforce (CRM) shares rose in after-hours trading following the release of its Q1 earnings, which beat estimates with adjusted EPS of $2.58 on revenue of $9.8 billion. The company's Q2 revenue guidance of $10.11-$10.16 billion also exceeded expectations, and FY26 revenue guidance was slightly raised to $41-$41.3 billion, citing a weakening dollar as a tailwind; a key metric, CRPO, rose 12% to $29.6 billion, also surpassing estimates.

Analysis

Salesforce reported first-quarter fiscal 2026 adjusted earnings per share of $2.58, a nearly 6% increase and slightly above the analyst consensus of $2.55. Revenue climbed 8% year-over-year to $9.8 billion, marginally exceeding the $9.75 billion expectation. A key metric, current remaining performance obligations (CRPO), which represents an aggregate of deferred revenue and order backlog, rose 12% to $29.6 billion, surpassing estimates of $29.04 billion, indicating a healthy pipeline. Following these results, Salesforce stock increased over 1% to $280.60 in extended trading. For the upcoming July quarter, the company projects revenue between $10.11 billion and $10.16 billion, ahead of the $10.02 billion consensus. Furthermore, Salesforce slightly raised its full-year fiscal 2026 revenue guidance to a range of $41 billion to $41.3 billion, up from its prior outlook of $40.5 billion to $40.9 billion, citing a weakening dollar as a beneficial factor. This positive financial update comes after CRM stock had retreated about 16% year-to-date. Strategically, Salesforce is enhancing its artificial intelligence offerings, evidenced by its recent agreement to acquire data-management software firm Informatica (INFA) for $8 billion in an all-cash deal; analysts estimate AI products could contribute a 1% revenue lift in fiscal 2026. Despite these positive developments, some investors remain focused on Salesforce's ability to improve operating margins amid slowing overall revenue growth. The stock currently holds an IBD Composite Rating of 79 out of 99.

Key Decisions for Investors

• Investors should consider the better-than-expected Q1 results and upwardly revised guidance as positive short-term catalysts, potentially signaling a trough after the stock's year-to-date decline.
• Monitor the integration of Informatica closely, as its successful incorporation is key to Salesforce's augmented AI strategy and realizing the projected 1% revenue lift from AI products in fiscal 2026.
• Given the backdrop of slowing revenue growth, continue to scrutinize Salesforce's ability to deliver on operating margin improvements as a critical driver for sustained value creation.
• Evaluate whether the current valuation, post-earnings pop but still down year-to-date, adequately reflects both the growth opportunities in AI and life sciences, and the ongoing challenges in margin expansion.